Under the Radar: Vaxcyte Stock Jumps After Pneumonia Vaccine Holds Up in Study -- WSJ
Dow Jones2026/10/05 16:48By Xavier Martinez Vaxcyte shares jumped more than 25% Monday after the company said its experimental pneumonia vaccine held up against the two shots now on the market in a large final-stage trial. The vaccine, called VAX-31, targets 31 strains of the bacteria that cause pneumonia, meningitis and bloodstream infections. It is set to compete with Pfizer's Prevnar 20, which covers 20 strains, and Merck's Capvaxive, which covers 21. Vaxcyte said VAX-31 showed immune responses comparable to the rival shots on all 28 strains it shares with them. The company also said VAX-31 produced stronger immune responses than the existing shots on three strains only it covers. It fell short of the study's main target on two strains against Merck's shot. The company expects to report data from two more trials in the first half of 2027, and said it plans to seek FDA approval of the shot in the first half of 2028. This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage). (END) Dow Jones Newswires October 05, 2026 12:48 ET (16:48 GMT)
By Xavier Martinez
Vaxcyte shares jumped more than 25% Monday after the company said its experimental pneumonia vaccine held up against the two shots now on the market in a large final-stage trial. The vaccine, called VAX-31, targets 31 strains of the bacteria that cause pneumonia, meningitis and bloodstream infections. It is set to compete with Pfizer's Prevnar 20, which covers 20 strains, and Merck's Capvaxive, which covers 21.
Vaxcyte said VAX-31 showed immune responses comparable to the rival shots on all 28 strains it shares with them. The company also said VAX-31 produced stronger immune responses than the existing shots on three strains only it covers. It fell short of the study's main target on two strains against Merck's shot. The company expects to report data from two more trials in the first half of 2027, and said it plans to seek FDA approval of the shot in the first half of 2028.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
October 05, 2026 12:48 ET (16:48 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Crypto prices
More
